4-Mar-2026 3:05 PM CST - Business Wire PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights. 2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing c
3-Mar-2026 6:00 AM CST - Business Wire PepGen to Participate in the Leerink Global Healthcare Conference PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available
12-Nov-2025 6:00 AM CST - Business Wire PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2025. This quarter was defined by the strong results from the 15 mg/kg cohort of our FREEDOM study, which showed unprecedented levels of splicing corre
3-Nov-2025 6:00 AM CST - Business Wire PepGen to Participate in Upcoming Investor Conferences PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference (Boston, MA) Monday, November 10, 2025 at 11:30 a.m. ET, Fireside Chat Stifel 2025 Healthc
7-Aug-2025 7:00 AM CST - Business Wire PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. This quarter, we made further progress in the development of our promising myotonic dystrophy type 1 program, PGN-EDODM1. With class-leading mean mis-
8-May-2025 7:00 AM CST - Business Wire PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. Our EDO platforms unique ability to efficiently deliver oligonucleotides into the nuclei of cells is the foundation of our differentiated pipeline,
2-Apr-2025 3:05 PM CST - Business Wire PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET. A webcast of the corporate presentation will be available on the "Even
4-Mar-2025 7:05 AM CST - Business Wire PepGen to Participate in Upcoming Investor Conferences PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference 2025 (Miami, FL) Tuesday, March 11, 2025 at 3:00 p.m. ET, Fireside Chat Stifel 2025 Virtual CNS Forum Wednesda
24-Feb-2025 6:30 AM CST - Business Wire PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2024, and recent corporate highlights. Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dos
4-Mar-2026 3:05 PM CST - Business Wire PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights. 2025 was a transformative year for PepGen as the Phase 1 FREEDOM trial delivered compelling data that set a new benchmark for splicing c
3-Mar-2026 6:00 AM CST - Business Wire PepGen to Participate in the Leerink Global Healthcare Conference PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida. A webcast of the event will be available
12-Nov-2025 6:00 AM CST - Business Wire PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2025. This quarter was defined by the strong results from the 15 mg/kg cohort of our FREEDOM study, which showed unprecedented levels of splicing corre
3-Nov-2025 6:00 AM CST - Business Wire PepGen to Participate in Upcoming Investor Conferences PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference (Boston, MA) Monday, November 10, 2025 at 11:30 a.m. ET, Fireside Chat Stifel 2025 Healthc
7-Aug-2025 7:00 AM CST - Business Wire PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. This quarter, we made further progress in the development of our promising myotonic dystrophy type 1 program, PGN-EDODM1. With class-leading mean mis-
8-May-2025 7:00 AM CST - Business Wire PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. Our EDO platforms unique ability to efficiently deliver oligonucleotides into the nuclei of cells is the foundation of our differentiated pipeline,
2-Apr-2025 3:05 PM CST - Business Wire PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET. A webcast of the corporate presentation will be available on the "Even
4-Mar-2025 7:05 AM CST - Business Wire PepGen to Participate in Upcoming Investor Conferences PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Leerink Partners Global Healthcare Conference 2025 (Miami, FL) Tuesday, March 11, 2025 at 3:00 p.m. ET, Fireside Chat Stifel 2025 Virtual CNS Forum Wednesda
24-Feb-2025 6:30 AM CST - Business Wire PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2024, and recent corporate highlights. Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dos
